Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹145Cr
Rev Gr TTM
Revenue Growth TTM
15.84%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

VITAL
VS
| Quarter | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | | | -2.6 | -17.9 | -13.6 | 32.4 | 40.2 | -2.1 |
| 0 | 46 | 51 | 51 | 48 | 50 | 61 | 62 | 60 |
Operating Profit Operating ProfitCr |
| | 20.0 | 15.2 | 10.0 | 3.8 | -3.5 | 7.4 | 9.4 | 7.3 |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 1 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
Depreciation DepreciationCr | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 2 |
| 0 | 11 | 9 | 5 | 3 | -1 | 5 | 6 | 4 |
| 0 | 3 | 2 | 1 | 0 | 1 | 1 | 1 | 1 |
|
Growth YoY PAT Growth YoY% | | | | -75.1 | -69.4 | -260.4 | 24.2 | 155.1 | -41.6 |
| | 13.7 | 10.0 | 3.5 | 3.7 | -6.5 | 3.5 | 2.6 | 2.1 |
| 0.0 | 0.0 | 0.0 | 0.1 | 0.8 | -1.3 | 1.0 | 0.7 | 0.6 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 102.6 | -15.8 | 36.3 | -1.0 |
| 46 | 102 | 98 | 123 | 121 |
Operating Profit Operating ProfitCr |
| 20.0 | 12.7 | 0.2 | 8.4 | 8.4 |
Other Income Other IncomeCr | 0 | 0 | 3 | 2 | 1 |
Interest Expense Interest ExpenseCr | 0 | 1 | 1 | 2 | 2 |
Depreciation DepreciationCr | 1 | 2 | 3 | 5 | 5 |
| 11 | 11 | 0 | 6 | 10 |
| 3 | 3 | 1 | 2 | 1 |
|
| | 1.9 | -116.2 | 411.4 | -23.8 |
| 13.7 | 6.9 | -1.3 | 3.0 | 2.3 |
| 11.8 | 4.5 | -0.5 | 1.7 | 1.3 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Equity Capital Equity CapitalCr | 7 | 24 | 24 | 24 |
| 8 | 66 | 60 | 68 |
Current Liabilities Current LiabilitiesCr | 45 | 25 | 37 | 48 |
Non Current Liabilities Non Current LiabilitiesCr | 21 | 23 | 16 | 41 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 61 | 93 | 58 | 75 |
Non Current Assets Non Current AssetsCr | 21 | 45 | 79 | 107 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | -13 | -8 | 14 | 6 |
Investing Cash Flow Investing Cash FlowCr | 1 | -26 | -35 | -30 |
Financing Cash Flow Financing Cash FlowCr | 18 | 58 | -9 | 25 |
|
Free Cash Flow Free Cash FlowCr | -22 | -18 | -7 | -40 |
| -167.3 | -103.1 | -1,073.0 | 151.8 |
CFO To EBITDA CFO To EBITDA% | -114.7 | -56.1 | 7,151.5 | 54.6 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 184 | 170 | 120 |
Price To Earnings Price To Earnings | 0.0 | 22.9 | 0.0 | 29.7 |
Price To Sales Price To Sales | 0.0 | 1.6 | 1.7 | 0.9 |
Price To Book Price To Book | 0.0 | 2.0 | 2.0 | 1.3 |
| 2.6 | 12.3 | 999.7 | 14.8 |
Profitability Ratios Profitability Ratios |
| 34.4 | 26.6 | 23.2 | 21.0 |
| 20.0 | 12.7 | 0.2 | 8.4 |
| 13.7 | 6.9 | -1.3 | 3.0 |
| 21.5 | 10.7 | 0.8 | 6.0 |
| 54.0 | 9.0 | -1.5 | 4.4 |
| 9.7 | 5.8 | -0.9 | 2.2 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
Vital Chemtech Limited is a prominent Indian manufacturer specializing in **phosphorus derivative chemistry**. Operating from the industrial hub of Gujarat, the company has established an integrated manufacturing model focused on downstream and specialty products. With a strategic emphasis on high-growth sectors such as **Pharmaceuticals, Agrochemicals, and Electric Vehicle (EV) battery chemicals**, the company is currently transitioning from the SME platform to the **Main Board** of Indian stock exchanges to facilitate its next phase of institutional growth.
---
### **Core Product Portfolio & Industrial Applications**
The company manufactures **6 core phosphorus-based products** on a purchase-order basis. These chemicals serve as critical intermediates across a diverse range of industrial value chains.
| Product | Key Applications | Target Industry Segments |
| :--- | :--- | :--- |
| **Phosphorus Trichloride (PCl3)** | Chlorinating agent; electrodeposition of metal on rubber. | Pesticides, surfactants, plasticizers, and medicinal products. |
| **Phosphorus Oxychloride (POCl3)** | Critical raw material for chemical reactions. | Pharma (Pantoprazole, Losartan, Oncology APIs), Agrochemicals, Gasoline additives. |
| **Phosphorus Pentachloride (PCl5)** | Catalyst and chlorinating agent; precursor for electrolytes. | Pharma (Antibiotics), Aluminum metallurgy, **EV Chemicals (Lithium Hexafluorophosphate)**. |
| **Phosphorus Pentoxide (P2O5)** | Laboratory reagent; synthesis material. | Pigments (Quinacridone), Textile Auxiliaries, Heat-insulating glass. |
| **Poly Phosphoric Acid (PPA)** | Dehydrating agent; catalyst for cumene production. | Pharma (Critical care APIs), Metal brightening, Gas stream drying. |
| **Phosphorus Pentasulfide (P2S5)** | Primary raw material for **ZDDP** (lubricant additive). | Lubricant additives, Safety matches, Pesticides, Pharmaceuticals. |
---
### **Manufacturing Infrastructure & Technological Edge**
Vital Chemtech operates a state-of-the-art, automated manufacturing complex in the **PCPIR (Petroleum, Chemicals and Petrochemicals Investment Region) of Dahej, Gujarat**.
* **Capacity Scaling:** The company has significantly expanded its cumulative manufacturing capacity from **13,200 MT** in **2022** to **28,800 MT** currently.
* **Automation:** Plant operations utilize **PLC (Programmable Logic Controller)** and **SCADA (Supervisory Control and Data Acquisition)** systems to ensure precision and safety.
* **Land Assets:** The facility is situated on a **9,100 Sq. Mt.** plot with **10%** land remaining for immediate expansion. Furthermore, an adjacent **18,000 Sq. Mt.** plot is secured for future large-scale growth.
* **Sustainability:** The site operates as a **Zero Liquid Discharge (ZLD)** plant, aligning with global ESG standards and minimizing environmental impact.
* **Quality Certifications:** The company holds **ISO 9001:2015**, **ISO 45001:2018**, and **ISO 14001:2015** certifications.
---
### **Strategic Market Positioning & Regulatory Compliance**
The company leverages its specialized focus on phosphorus chemistry to maintain a competitive moat, while adhering to rigorous domestic and international standards.
* **BIS Leadership:** Vital Chemtech was the first company to receive the **BIS License (IS 11744)** for **Phosphorus Pentachloride** in **June 2024**. It also secured **BIS registration** for **Phosphorous Trichloride** (May 2024) and **Polyphosphoric Acid** (October 2025).
* **Intellectual Property:** Holds **Trademark Registration (No. 5535672)** under **Class 1** for its range of industrial and scientific chemicals.
* **Regulatory Adherence:** Operations comply with the **Chemical Weapons Convention Act (2000)**, **The Poison Act (1919)**, and **The Petroleum Act (1934)**.
* **Customer De-risking:** The company maintains a highly diversified client base. **No single customer** contributes more than **10%** of total revenue, and the **Top 5 clients** collectively account for less than **25%** of the topline.
---
### **Financial Performance & Subsidiary Growth**
The company demonstrated a significant financial turnaround in **FY 2024-25**, transitioning to consolidated profitability despite headwinds in the broader chemical sector.
**Financial Summary (INR Crore):**
| Metric | FY 2024-25 (Consolidated) | FY 2023-24 (Consolidated) | FY 2024-25 (Standalone) |
| :--- | :---: | :---: | :---: |
| **Total Income** | **135.98** | **101.61** | **122.22** |
| **Net Profit / (Loss)** | **4.06** | **(1.30)** | **4.63** |
| **YoY Income Growth** | **33.8%** | - | **16.35%** |
* **Profitability Turnaround:** The group moved from a consolidated loss of **1.30 crore** to a profit of **4.06 crore**. Standalone PAT grew by **15.02%**.
* **Subsidiary Contributions:**
* **Vital Alkoxides Private Limited:** Achieved **EBITDA positive** status in its first full year of operations (**2025**) and secured its **Provisional Consent Order (CC&A)** from the GPCB.
* **Vital Synthesis Limited:** Project activities are in final stages; commercial production is slated for **FY 2025-26**.
* **Capital Management:** The company utilized cash surpluses to pay down **significant debt** and transferred **31.80 Lakhs** to **General Reserves** in FY 2024-25.
---
### **Future Growth Strategy & Capital Market Migration**
Vital Chemtech is positioning itself to benefit from the "China Plus One" strategy and the projected growth of the Indian chemical industry to **$1 trillion by 2040**.
* **Main Board Migration:** In **November 2025**, the Board approved the migration from **NSE Emerge** to the **Main Board** of both the **NSE** and **BSE**. This move is designed to enhance share liquidity and attract institutional investors.
* **Talent Retention:** The company introduced the **Vital Employee Stock Option Scheme 2025 (ESOS-2025)**, authorizing up to **4,80,000** equity shares for key personnel.
* **New Frontiers:** Strategic focus is shifting toward **EV battery chemicals** (Lithium Hexafluorophosphate precursors), **Electronics chemicals**, and **Green chemistry** solutions.
* **Export Expansion:** Having commenced exports in **2022**, the company is actively expanding its footprint in international markets, including **Saudi Arabia**.
---
### **Risk Management & Operational Safety**
The company manages risks through a formal mapping and trend analysis framework, addressing both industrial hazards and macroeconomic volatility.
* **Safety Incident:** In **May 2025**, a pipeline gasket burst at the **P2S5 Plant** resulted in **one fatality** and two injuries. While this caused a **temporary disruption** at that specific block, other production areas remained operational. The company has since reinforced **proactive maintenance protocols**.
* **Environmental Risk:** Managed through **Zero Liquid Discharge** technology and strict adherence to GPCB mandates.
* **Macro Risks:** The company monitors **persistent inflation**, **rising interest rates**, and **geopolitical instability** (e.g., the Russia-Ukraine conflict) which may impact global demand and supply chains.
* **Solvency:** Statutory audits confirm **no material uncertainty** regarding the company’s ability to meet its short-term liabilities.